Becton Dickinson to acquire Bard for $24bn

Medical technology company Becton Dickinson (BD) will acquire C R Bard, a business in the same industry, for $24 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

J&J names two-decade veteran as chief IP counsel

10 September 2026 The senior lawyer previously led Johnson & Johnson’s global pharmaceutical patent team, advising on patent portfolios, R&D, licensing, M&A and litigation.

Pharma

J&J unit win shuts door on Sandoz generic launch

10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.

MedTech

Abbott clinches 18-country PI in glucose monitoring feud

9 September 2026 The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.

More features

J&J names two-decade veteran as chief IP counsel

J&J unit win shuts door on Sandoz generic launch

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

Sun Pharma import ban back in force after Squires intervention

Becton Dickinson to acquire Bard for $24bn

More on this story

Editor's picks

Editor's picks

More features